Study of AFP464 +/- Faslodex in ER + Breast Cancer
AFP464 is an investigational agent which may be effective in the treatment of cancer. The purpose of this study is to test the efficacy of AFP464 +/- Faslodex in ER+ breast cancer patients.
Breast Neoplasm
DRUG: AFP464|DRUG: AFP464 + Faslodex
Clinical Benefit Response, Clinical Benefit Response (CBR) defined as Complete Response, Partial Response or Stable Disease for 6 months., 6 months
Progression Free Survival, Determination of progression free survival, 6 months|Number of participants with adverse events, Determination of the number of patients who experience adverse events, 6 months
This is a randomized, open-label study. Patients will be randomized in a 1:1 ratio to single arm AFP464, or AFP464+Faslodex. Patients will be treated until disease progression is noted.